Mesoblast Ltd (MEOBF.PK)

MEOBF.PK

About

Mesoblast Limited (Mesoblast) is engaged in the commercialization of intellectual property associated with the isolation, culture and scale-up of adult stem cells referred to as mesenchymal precursor cells (MPCs). Mesoblast operates in one segment, which includes the research and development of MPCs. The Company’s cardiovascular... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.64
Market Cap (Mil.):	$1,734.83
Shares Outstanding (Mil.):	315.42
Dividend:	--
Yield (%):	--

Financials

	MEOBF.PK	Industry	Sector
P/E (TTM):	--	53.09	35.13
EPS (TTM):	-0.19	--	--
ROI:	-8.09	0.99	18.83
ROE:	-11.54	1.98	19.68

Latest News about MEOBF.PK

» More MEOBF.PK News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - MESOBLAST LTD (MSB-AU) Provider: Thomson Reuters Stock Report	$25.00 Buy
Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Mesoblast Limited - Circulation Research Publishes AMI Preclinical Trial Results Provider: irasia.com	$12.00 Buy
Wright Investors Service Comprehensive Report for Mesoblast Ltd Provider: Wright Reports	$449.00 Buy
Mesoblast Limited - Appendix 4C - Quarterly Provider: irasia.com	$58.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.